These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 26078489)

  • 1. Screening Mild and Major Neurocognitive Disorders in Parkinson's Disease.
    Lucza T; Karádi K; Kállai J; Weintraut R; Janszky J; Makkos A; Komoly S; Kovács N
    Behav Neurol; 2015; 2015():983606. PubMed ID: 26078489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic utility of Montreal Cognitive Assessment in the Fifth Edition of Diagnostic and Statistical Manual of Mental Disorders: major and mild neurocognitive disorders.
    Liew TM; Feng L; Gao Q; Ng TP; Yap P
    J Am Med Dir Assoc; 2015 Feb; 16(2):144-8. PubMed ID: 25282632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnosis and therapy for neurocognitive disorders in Parkinson's disease].
    Lucza T; Karádi K; Komoly S; Janszky J; Kállai J; Makkos A; Kovács M; Weintraut R; Deli G; Aschermann Z; Kovács N
    Orv Hetil; 2015 Jun; 156(23):915-26. PubMed ID: 26027599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity and specificity of Addenbrooke's Cognitive Examination, Mattis Dementia Rating Scale, Frontal Assessment Battery and Mini Mental State Examination for diagnosing dementia in Parkinson's disease.
    Kaszás B; Kovács N; Balás I; Kállai J; Aschermann Z; Kerekes Z; Komoly S; Nagy F; Janszky J; Lucza T; Karádi K
    Parkinsonism Relat Disord; 2012 Jun; 18(5):553-6. PubMed ID: 22405839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing Sensitivity and Specificity of Addenbrooke's Cognitive Examination-I, III and Mini-Addenbrooke's Cognitive Examination in Parkinson's Disease.
    Lucza T; Ascherman Z; Kovács M; Makkos A; Harmat M; Juhász A; Janszky J; Komoly S; Kovács N; Dorn K; Karádi K
    Behav Neurol; 2018; 2018():5932028. PubMed ID: 30369997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addenbrooke's Cognitive Examination validation in Parkinson's disease.
    Reyes MA; Perez-Lloret S; Roldan Gerschcovich E; Martin ME; Leiguarda R; Merello M
    Eur J Neurol; 2009 Jan; 16(1):142-7. PubMed ID: 19049504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease.
    Faust-Socher A; Duff-Canning S; Grabovsky A; Armstrong MJ; Rothberg B; Eslinger PJ; Meaney CA; Schneider RB; Tang-Wai DF; Fox SH; Zadikoff C; Kennedy N; Chou KL; Persad C; Litvan I; Mast BT; Gerstenecker AT; Weintraub S; Reginold W; Marras C
    Dement Geriatr Cogn Disord; 2019; 47(4-6):187-197. PubMed ID: 31315127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An assessment of Movement Disorder Society Task Force diagnostic criteria for mild cognitive impairment in Parkinson's disease.
    Uysal-Cantürk P; Hanağası HA; Bilgiç B; Gürvit H; Emre M
    Eur J Neurol; 2018 Jan; 25(1):148-153. PubMed ID: 28941002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the Turkish Version of the Montreal Cognitive Assessment Scale (MoCA-TR) in patients with Parkinson's disease.
    Ozdilek B; Kenangil G
    Clin Neuropsychol; 2014; 28(2):333-43. PubMed ID: 24528299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is the Montreal Cognitive Assessment (MoCA) test better suited than the Mini-Mental State Examination (MMSE) in mild cognitive impairment (MCI) detection among people aged over 60? Meta-analysis.
    Ciesielska N; Sokołowski R; Mazur E; Podhorecka M; Polak-Szabela A; Kędziora-Kornatowska K
    Psychiatr Pol; 2016 Oct; 50(5):1039-1052. PubMed ID: 27992895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive screening in Parkinson's disease: Comparison of the Parkinson Neuropsychometric Dementia Assessment (PANDA) with 3 other short scales.
    Gasser AI; Calabrese P; Kalbe E; Kessler J; Rossier P
    Rev Neurol (Paris); 2016 Feb; 172(2):138-45. PubMed ID: 26494570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening of cognitive impairment in patients with Parkinson's disease: diagnostic validity of the Brazilian versions of the Montreal Cognitive Assessment and the Addenbrooke's Cognitive Examination-Revised.
    Sobreira E; Pena-Pereira MA; Eckeli AL; Sobreira-Neto MA; Chagas MH; Foss MP; Cholerton B; Zabetian CP; Mata IF; Tumas V
    Arq Neuropsiquiatr; 2015 Nov; 73(11):929-33. PubMed ID: 26517216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validity and reliability of the Persian version of the Montreal Cognitive Assessment (MoCA-P) scale among subjects with Parkinson's disease.
    Badrkhahan SZ; Sikaroodi H; Sharifi F; Kouti L; Noroozian M
    Appl Neuropsychol Adult; 2020; 27(5):431-439. PubMed ID: 30821505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of the Polish versions of the Montreal Cognitive Assessment 7.2 and the Mini-Mental State Examination as screening instruments for the detection of mild neurocognitive disorder.
    Sokołowska N; Sokołowski R; Oleksy E; Kasperska P; Klimkiewicz-Wszelaki K; Polak-Szabela A; Podhorecka M; Kędziora-Kornatowska K
    Neurol Neurochir Pol; 2020; 54(5):440-448. PubMed ID: 32808669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening utility of the Montreal Cognitive Assessment (MoCA): in place of--or as well as--the MMSE?
    Larner AJ
    Int Psychogeriatr; 2012 Mar; 24(3):391-6. PubMed ID: 22014176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effectiveness of the Montreal Cognitive Assessment 7.2 and the Mini-Mental State Examination in the detection of mild neurocognitive disorder in people over 60 years of age. Preliminary study.
    Sokołowska N; Sokołowski R; Polak-Szabela A; Mazur E; Podhorecka M; Kędziora-Kornatowska K
    Psychiatr Pol; 2018 Oct; 52(5):843-857. PubMed ID: 30584818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive screening in substance users: Diagnostic accuracies of the Mini-Mental State Examination, Addenbrooke's Cognitive Examination-Revised, and Montreal Cognitive Assessment.
    Ridley N; Batchelor J; Draper B; Demirkol A; Lintzeris N; Withall A
    J Clin Exp Neuropsychol; 2018 Mar; 40(2):107-122. PubMed ID: 28436744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic utility of the Addenbrooke's Cognitive Examination - III (ACE-III), Mini-ACE, Mini-Mental State Examination, Montreal Cognitive Assessment, and Hasegawa Dementia Scale-Revised for detecting mild cognitive impairment and dementia.
    Senda M; Terada S; Takenoshita S; Hayashi S; Yabe M; Imai N; Horiuchi M; Yamada N
    Psychogeriatrics; 2020 Mar; 20(2):156-162. PubMed ID: 31448862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for Cognitive Impairment in Parkinson's Disease: Improving the Diagnostic Utility of the MoCA through Subtest Weighting.
    Fengler S; Kessler J; Timmermann L; Zapf A; Elben S; Wojtecki L; Tucha O; Kalbe E
    PLoS One; 2016; 11(7):e0159318. PubMed ID: 27437705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson's disease-cognitive rating scale: psychometrics for mild cognitive impairment.
    Fernández de Bobadilla R; Pagonabarraga J; Martínez-Horta S; Pascual-Sedano B; Campolongo A; Kulisevsky J
    Mov Disord; 2013 Sep; 28(10):1376-83. PubMed ID: 23873810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.